BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 15306095)

  • 1. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
    Wolbrette DL
    Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [QTc-prolonging drugs and the risk of sudden death].
    Reingardiene D; Vilcinskaite J
    Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph].
    Shinozaki K
    Yakugaku Zasshi; 2010 Nov; 130(11):1597-601. PubMed ID: 21048421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lengthening of QT interval by antipsychotic drugs].
    Haverkamp W; Deuschle M
    Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of the QT interval: a review of the literature.
    Elming H; Sonne J; Lublin HK
    Acta Psychiatr Scand; 2003 Feb; 107(2):96-101. PubMed ID: 12534434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
    Wolbrette D
    Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].
    Trojak B; Pinoit JM; André D; Bonin B; Gisselmann A
    Presse Med; 2006 Apr; 35(4 Pt 2):699-704. PubMed ID: 16614617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
    Kecskeméti V
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
    Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
    Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced torsade de pointes: from molecular biology to bedside.
    Tamargo J
    Jpn J Pharmacol; 2000 May; 83(1):1-19. PubMed ID: 10887935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced q-T prolongation.
    Kao LW; Furbee RB
    Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.